Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly administered to children and
adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflammatory bowel disease …

Non-tuberculous mycobacteria (NTM) are a large family of acid-fast bacteria, widespread in
the environment. In children, NTM cause lymphadenitis, skin and soft tissue infections, and …

Background Adult patients receiving anti-TNFα drugs are at increased risk of tuberculosis
(TB), but studies in pediatric populations are limited, and the best strategy for latent …

Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with
tumor necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care …

Background: Biological therapies using anti-tumor necrosis factor (TNF)-α agents have an
important impact in the treatment of inflammatory bowel disease, rheumatoid arthritis …

Incidence of inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and
ulcerative colitis (UC), is increasing worldwide. Children with IBDs have a dysfunctional …

Introduction: The incidence of pediatric inflammatory bowel disease (IBD) is rising, as is the
employment of immunosuppressive and biological drugs. Most patients with IBD receive …

According to the US Food and Drug Administration, biologics represent a wide range of
products, including vaccines, blood components, allergenics, somatic cells, gene therapy …

Infections in pediatric patients with inflammatory bowel diseases may occur as a
complication of the underlying disease process, a secondary effect of pharmacologic …

Crohn disease (CD) is a chronic inflammatory condition that can affect any portion of the
gastrointestinal tract from the mouth to the perianal area. Medical therapy is a cornerstone of …